|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 管理潜在地 resectable colorectal 癌症肝转移显示文摘 Colorectal cancer is a very common malignancy worldwide and development of liver metastases,both synchronous or metachronous,is a common event.Of all patients with metastatic colorectal cancer,up to 77% have a liver-only disease and approximately 10%-20% of patients with colorectal liver metastases are considered resectable at the time of diagnosis.Surgical resection of liver metastases remains the best treatment option and it is associated with a survival plateau and a 20%-25% of long-term survivors.Perioperative chemotherapy for resectable liver metastases may improve resecability of liver metastases and disease free survival,but its impact on overall survival is still unclear and more studies are needed.Moreover,preoperative chemotherapy can increase postoperative complications.Further studies are needed to define the role of adjuvant chemotherapy after a R0 resection of liver metastases and to define the criteria for a better selection of patients candidate to hepatectomy.New strategies such as targeted therapies are emerging with promising results.Optimal management requires a multidisciplinary approach,local and systemic,but it is a still pending question.Colorectal liver metastases represent a major challenge for oncologists and surgeons.In this review will be analyzed available data about assessment and management of the patients with potentially resectable colorectal liver metastases. | Fausto Meriggi Paola Bertocchi Alberto Zaniboni | 2013 | World Journal of Gastrointestinal Surgery2013，5，5： | 6 |
| 2 | Thyroid carcinoma showing thymus-like differentiation: Case presentation of a young man显示文摘Ectopic thymic tissue can be present in the thyroid gland and a carcinoma showing thymus-like differentiation(CASTLE) may arise from such tissue. We are reported the case of a 26-year-old man with CASTLE, with cervical subcutaneous nodules relapse, who showed a good response to treatment with surgery, chemotherapy and radiotherapy. The problematic aspect of this case was the diagnosis; only on review were we able to make a final diagnosis. CASTLE is a very rare neoplasm. It is important to differentiate this cancer from others tumors such as primary or metastatic squamous cell carcinoma of the head and neck or squamous cell thyroid carcinoma, because the therapy and prognosis are different.Diagnosis is complicated and requires careful histological analysis(CD5- and P63-positive with presence of Hassall's corpuscles); unfortunately there is no gold standard treatment so, in this case, we administered a sandwich of chemotherapy and radiotherapy. | Chiara Abeni Chiara Ogliosi Luigina Rota Paola Bertocchi Alessandra Huscher Giordano Savelli Mariano Lombardi Alberto Zaniboni | 2014 | World Journal of Clinical Oncology2014，5，5： | 5 |
| 3 | Pancreatic cancer:New hopes after first line treatment显示文摘Pancreatic cancer is the fourth leading cause of cancerrelated death worldwide.Extensive research has yielded advances in first-line treatment strategies,but there is no standardized second-line therapy.In this review,we examine the literature trying to establish a possible therapeutic algorithm. | Francesca Aroldi Paola Bertocchi Giordano Savelli Edoardo Rosso Alberto Zaniboni | 2016 | World Journal of Gastrointestinal Oncology2016，8，9： | 2 |
| 4 | The emerging role of oxaliplatin in the treatment of gastric cancer 显示文摘 | Zaniboni A Meriqqi F | 2005 | J Chemother2005，17，6： | 1 |
| 5 | Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer显示文摘 | Meriggi F Zaniboni A | 2010 | Current Gerontol Geriatrics Research2010，4，34： | 1 |
| 6 | Navelbine(N),leucovorin(L),and fluorouracil (52FU)(FLN) for triple-negative metastatic breast cancer (TNBC)显示文摘 | Zaniboni A Meriggi F Rizzi A | 2008 | J Clin Oncol2008，26，15： | 1 |
| 7 | Seizures in acute stroke: incidence, risk factors and prognosis 显示文摘 | Procaccianti G Zaniboni A Rondeli F | 2012 | Neu- roepidemiology2012，39，1： | 1 |
| 8 | Oxaliplatin as single agentin previously untreated colorectal carcinoma patients: a phase Ⅱ multicentric study 显示文摘 | Diaz- Rubio E Sastre J Zaniboni A | 1998 | Ann Oncol1998，9，1： | 1 |
| 9 | The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD(Italian Group for the Study of Digestive Tract) cancer phase Ⅱ trial 显示文摘 | Mosconi S Cascinu S Zaniboni A | 2000 | Tumori2000，86，6： | 1 |
| 10 | Pancreatic adenocarcinoma:Beyond first line,where are we?显示文摘Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent years.To date,chemotherapy is still the standard of care for advanced metastatic disease,unfortunately providing only a slight advantage in terms of survival.The molecular and cellular characteristics of pancreatic cancer cells,as well as the cells that characterize the pancreatic tumour microenvironment,are the basis of the mechanisms of resistance to treatment.After progression during first-line treatment,few patients are eligible for secondline treatment due to the loss of performance status.To date,a clear survival advantage has not yet been demonstrated for second-line chemotherapy.Precision medicine could be the key to increasing responses to cancer treatment and finally impacting survival in this difficult-to-treat disease.In this review,we analyze current recommendations in the second-line setting and potential future prospects. | Sara Cherri Silvia Noventa Alberto Zaniboni | 2021 | World Journal of Gastroenterology2021，27，17： | 1 |
| 11 | Dental implants placed in grafted maxillary sinuses: a retrospective analysis of clinical outcome according to the initial clinical situation and a proposal of defect classification显示文摘 | Chiapasco M Zaniboni M Rimondini L | 2008 | Clin Oral Implants Res2008，19，4： | 1 |
| 12 | Phase ⅡSyudy of Taxol combined with ifosfamide and carboplatin in the treatment of stage Ⅲ B-Ⅳ non-small-cell lung cancer显示文摘 | Ardizzoni A De Marinis F | 2003 | Am J Clin Oncol2003，26，1： | 1 |
| 13 | Bone augmentation procedures in implant dentistry 显示文摘 | Chiapasco M Casentini P Zaniboni M | 2009 | Int J Oral Maxillofac Implants2009，，24： | 1 |
| 14 | The emerging role of oxaliplatin in the treatment of gastric cancer显示文摘 | Zaniboni A Meriggi F | 2005 | J Chemother2005，17，6： | 1 |
| 15 | A randomized trial of adjuvant5-fluoruracil and folinic acid administered to patients with colon carcinoma:long term results and evaluation of the indicators of health-related quality of life显示文摘 | Zaniboni A Labianca R Massoni S | 1998 | Cancer1998，82，12： | 1 |
| 16 | The emerging role of oxaliplatin in the treatment of gastric cancer显示文摘 | Zaniboni A Meriggi F | 2005 | J Chemother2005，17，6： | 1 |
| 17 | A randomized trial of adjuvant 5-fluoniracil and folinic acid administered to patients with colon careinoma:long term results and evaluation of the indicators of health-related quality of life 显示文摘 | Zaniboni A Labianca R Marsoni S | 1998 | Cancer1998，82，10： | 1 |
| 18 | A video-polygraphic analysis of the cataplectic attack显示文摘 | Rubboli G d′Orsi G Zaniboni A | | 0，，： | 1 |
| 19 | Oxaliplatin,5-fluorouracil and leucovofin in patients with advanced or metastatic gastric cancer显示文摘 | Cavanna L Zaniboni F Lazzaro A | | 0，，08： | 1 |
| 20 | OxaliplaLin as single agent in previously untreated colorrrectal carcinoma patients=A phase I1 multicentric study显示文摘 | Duaz-gubio E Sasre J Zaniboni A | 1998 | Ann Oncol1998，9，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员